Bladder cancer

Lore & Background

The most common symptom of bladder cancer is visible blood in the urine (haematuria) despite painless urination, affecting around 75% of people eventually diagnosed. Some have microscopic haematuria, pain while urinating, or no symptoms. Women with bladder cancer and haematuria are often misdiagnosed with urinary tract infections, delaying treatment. Around 5% of people have tumors that have already spread at diagnosis, most commonly to bones, lungs, liver, and nearby lymph nodes.

Diagnosis typically involves cystoscopy, where a thin camera is threaded through the urethra into the bladder. Suspected tumors are removed via transurethral resection of bladder tumor (TURBT) and examined by a pathologist.

Reader's Guide

Bladder cancer is a significant global health burden, with half a million new cases and 200,000 deaths annually. Its primary risk factor is tobacco smoking, which causes about half of all cases. The disease is most commonly diagnosed after visible blood in the urine, though many with this symptom do not have cancer. Diagnosis relies on cystoscopy and tissue biopsy, with staging determining prognosis and treatment. Non-muscle-invasive bladder cancer has the best prognosis and is treated with surgical removal and sometimes chemotherapy or immune-stimulating therapies. Muscle-invasive disease often requires bladder removal (radical cystectomy). Metastatic bladder cancer has the worst prognosis, with average survival of one year, and is treated with chemotherapy, immune checkpoint inhibitors, and enfortumab vedotin. The disease's association with age (average diagnosis at 73) and environmental exposures underscores the importance of prevention and early detection.

Did You Know?

• Tobacco smoking causes around half of all bladder cancer cases.
• Around 75% of people with bladder cancer have visible blood in their urine at diagnosis.
• The average survival for metastatic bladder cancer is one year from diagnosis.

The Body's Early Warnings

The most recognizable signal of bladder cancer is the appearance of blood in the urine, a condition known as haematuria, which eventually appears in roughly three-quarters of those who go on to receive a diagnosis. What makes this particularly unsettling is that the urination itself is typically painless, meaning the body offers little other alarm. A smaller subset of patients presents with microscopic haematuria detectable only under a microscope, or with discomfort during urination, while others show no symptoms whatsoever and are discovered incidentally during unrelated imaging. In rarer instances, a growing tumor obstructs urine flow, causing the kidneys to swell and producing a deep ache along the flank between the ribs and hips. It is crucial to note that the vast majority of people who notice blood in their urine do not have cancer—only about 22 percent of those with visible haematuria and 5 percent of those with microscopic traces are ultimately diagnosed. Tragically, women presenting with haematuria are frequently misattributed a urinary tract infection, which can delay the correct diagnosis and the start of treatment.

Mapping the Disease: Diagnosis and Staging

Once suspicion arises, the diagnostic workup centers on cystoscopy, widely regarded as the gold standard. A thin, flexible camera is threaded through the urethra into the bladder, allowing the physician to visually survey the interior for abnormal tissue. This technique excels at spotting papillary tumors—those with a finger-like architecture that project into the urine-holding chamber—but it is less reliable for small, flat carcinoma in situ lesions. To improve detection of these harder-to-see tumors, a variant called blue-light cystoscopy injects a dye called hexaminolevulinate that preferentially accumulates in cancer cells; when the cystoscope emits blue light, the dye fluoresces, making tiny lesions far easier to identify. Any suspicious growth is then excised during the same session in a procedure known as transurethral resection of bladder tumor, along with a sample of underlying muscle, and sent to a pathologist. If the resection is incomplete or the tumor is deemed high-risk, a second resection is scheduled four to six weeks later. Beyond the scope, clinicians also perform physical examinations, collect urine for cytology or molecular markers such as BTA protein and NMP22, and image the upper urinary tract using contrast-enhanced CT, MRI, or ultrasound.

Treatment Pathways and Prognosis

The course of treatment and the outlook for survival hinge almost entirely on how far the tumor has penetrated, a determination captured by a staging scale from zero to four. Patients whose cancer remains confined to the bladder lining enjoy the most favorable prognosis. Their tumors are typically excised surgically, followed by a course of chemotherapy or one of several immune-stimulating therapies designed to prevent recurrence. When a tumor has grown into or through the bladder muscle, or when it keeps returning after initial removal, surgeons often perform a radical cystectomy—the complete removal of the bladder. The most devastating scenario is metastatic disease, in which cancer cells have colonized distant organs such as the bones, lungs, liver, or regional lymph nodes. On average, patients in this group survive roughly one year from the time of diagnosis. Their treatment regimens combine conventional chemotherapy with immune checkpoint inhibitors and, more recently, the antibody-drug conjugate enfortumab vedotin. The staging system thus serves as a critical compass, directing clinicians toward the most appropriate and aggressive level of intervention for each individual case.

Who Is at Risk and the Global Toll

Bladder cancer is a substantial global health burden, with approximately 500,000 new diagnoses and 200,000 deaths recorded each year. The disease predominantly strikes older adults, with the average age at diagnosis sitting at 73. Among all identifiable risk factors, tobacco smoking stands as the single greatest contributor, accounting for roughly half of all cases. Beyond smoking, occupational or environmental exposure to certain toxic chemicals elevates risk, and in regions where the parasitic tropical infection schistosomiasis is endemic, the likelihood of developing bladder cancer rises noticeably. The cellular origin of the tumor also varies: over 90 percent of cases arise from urothelial, or transitional, cells that line the bladder's interior. About 5 percent are squamous cell cancers originating from a rarer cell type in the lining, a subtype that is disproportionately represented in countries with high schistosomiasis prevalence. A small fraction, up to 2 percent, belong to other histological categories. Understanding these risk profiles is essential for targeted screening and prevention strategies in the populations most vulnerable to the disease.

Gallery